clinical trial · NCT06284954
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
argenx·phase2·active not recruiting·n = 3
DermatomyositisMyositisEmpasiprubart IVPlacebo IV
brief summary
This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).
started
Aug 20, 2024
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Sep 25, 2025
official title
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol